Late-breaking phase 3 data at 2022 aaaai annual meeting show dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

Tarrytown, n.y. and paris, feb. 26, 2022 /prnewswire/ -- in this phase 3 trial, dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naÏve patients uncontrolled on antihistamines data reinforce the potential of targeting il-4 and il-13, key drivers of type 2 inflammation, in this complex chronic disease regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced detailed positive results for dupixent® (dupilumab) in patients with chronic spontaneous urticaria (csu) who are biologic-naÏve (i.e.
REGN Ratings Summary
REGN Quant Ranking